Work

ประสิทธิภาพและความปลอดภัยในการใช้เคตามีน และเอสเคตามีนในการรักษาโรคซึมเศร้า

Year: 2020
Type: article
Abstract: Background : Accumulated data have confirmed ketamine’s and Esketamine’santidepressant effects. On March 2019 the U.S. Food and Drug Administration (FDA)approved esketamine nasal spray in conjunction with an oral antidepressant fortreatment resistant depression (TRD). However, as it is used in the real world, more datawill be required.Objective : This paper will shortly review current data focused on the efficacy andsafety of Ketamine and Esketamine as a treatment for TRD.Methods : A literature search was conducted using the following databases: MEDLINE,Embase, PubMed, and the Cochrane Library for articles published between 2000-2019.The search was limited to articles written in English and Thai languages, using keywords:Ketamine, Esketamine, Arketamine, Treatment resistant depression.Result : Ketamine and Esketamine appear to be effective treatments when combinedwith oral antidepressants in patients with TRD. The special effect of esketamine israpid onset of antidepressant activity; a significant benefit for high-risk suicidal patients.Esketamine, an enantiomer of ketamine, works as a more potent NMDA receptorantagonist. Moreover, a number of studies have suggested that esketamine has lowerside effects than Ketamine. Evidence underpinning esketamine’s FDA approval (basedon 29 studies) shows greater efficacy than currently available adjunctive medications.However, the FDA asked for 3 years follow-up from esketamine trials and implementeda risk and benefit assessment. More adverse events were reported from esketaminewhen compared with placebo, but generally most of the adverse events resolved thesame day.Conclusion : Ketamine and Esketamine show great benefit and may be an alternativemedication for TRD. However, future study should be conducted to gather more datato address safety, efficacy and tolerability.
Language: Thai
Field: Medicine
Open Access status: bronze
OpenAlex ID: W7216684181
FWCI:
Cites: 22
Cited by:
Related to: 10